November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 20th, 2026Podcast: Bessel van der Kolk, MD, on Trauma, Attachment, and the Limits of Pharmacotherapy for PTSDBessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.Read more
November 20th, 2026Emestedastat for Alzheimer Disease Falls Short Overall, Signals Subgroup BenefitEmestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.Read more
November 20th, 2026Long-Acting Injectable Antipsychotics: Balancing Evidence, Ethics, and Patient CareIn this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.Read more
November 19th, 2026Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 YearsLeqembi shows lower progression rate in Alzheimer disease over 3 years, shows new data.Read more
November 19th, 2026Podcast: NIH Team Details Path From Ketamine Metabolite Discovery to Phase 2 Trials2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.Read more
November 18th, 2026Why Depression Subtypes Matter: Lessons From 25 Years in the ClinicExplore how clinicians subtype depression using severity, stressors, suicidality, sleep, and anxiety patterns to sharpen diagnosis, guide treatment, and build trust.Read more
November 18th, 20262027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSDLearn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more. Read more